调节动脉粥样硬化(AS)中巨噬细胞和T淋巴细胞等炎症细胞的活性，有助于促进AS斑块的稳定。我们在前期的研究中，成功研制了一种新型、特异性人Kv1.3（hKv1.3）通道阻滞剂- - 抗hKv1.3-E314肽段抗体。该抗体能阻滞人巨噬细胞膜表面的Kv1.3通道，有效地调节AS的固有免疫，改善巨噬细胞的胆固醇代谢。Kv1.3通道可能是AS良好的干预靶点。进一步研究须阐明Kv1.3通道对AS适应性免疫的调节作用及机制。我们设想，Kv1.3通道能够调节T淋巴细胞介导的AS促炎/抗炎反应平衡，促进AS斑块的稳定。我们拟研制抗hKv1.3-E314肽段单克隆抗体，阻滞人AS中T细胞膜上的Kv1.3通道，通过离体和在体实验，观察其对T细胞的分泌、归巢和迁移、分化功能的作用及机制。本研究将阐明Kv1.3通道调节AS适应性免疫的作用及分子机制, 从而为全面评价Kv1.3通道能否作为AS的干预靶点提供实验依据。

Modulation of the activities of macrophages and T lymphocytes contributes to the stability of atherosclerotic plaque. In the preliminary study, we successfully invented a novel specific human Kv1.3 (hKv1.3) channel blocker-the antibody against the hKv1.3-E314 peptide. By blocking Kv1.3 channels expressed on human macrophage membranes, the antibody played an important role in the modulation of atherosclerosis (AS) innate immunity and exhibited a beneficial effect on cholesterol metabolism, which suggests that the Kv1.3 channel may be a good target for the treatment of AS. Further researches are needed to address the role of the Kv1.3 channel in AS adaptive immunity. We suppose that the Kv1.3 channel can regulate the imbalance between T lymphocyte-mediated pro-inflammatory and anti-inflammatory response in AS, which promotes the stability of AS plaque. We intend to develop the monoclonal antibody against the hKv1.3-E314 peptide as an agent to specifically block Kv1.3 channels expressed on T lymphocyte membranes in AS. In vitro and vivo experiments are going to be performed around the effect and mechanism of Kv1.3 blockade on secretion, homing, migration and differentiation of T lymphocytes in AS. The results will clarify the role of Kv1.3 channels in AS adaptive immunity. This study will provide experimental evidence for comprehensive evaluation about the Kv1.3 channel as a target for the treatment of AS.